Katja Werlenius

3PUBLICATIONS
8CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 20, 2026
MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.

|Nov 12, 2021
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.

Katja Werlenius, Giuseppe Stragliotto, Michael Strandeus

|Feb 14, 2020
Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients.

Katja Werlenius, Boglarka Fekete, Malin Blomstrand

Pageof 1

Frequent Collaborators

1 joint publications

Bertil Rydenhag

1 joint publications

Sara Kinhult

1 joint publications

Martin Hallbeck

1 joint publications

Zdenek Rohan